3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Adenocarcinoma, Follicular
1
Interventions
Magnetic Resonance Spectroscopy
10
trametinib
7
Nivolumab
7
selpercatinib
6
pembrolizumab
6
dabrafenib
6
Iodine-131
6
Specimen Handling
5
Biopsy
5
lenvatinib
4
Vemurafenib
4
Iodine-124
4
durvalumab
3
cabozantinib
3
binimetinib
3
Ipilimumab
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Cyclophosphamide
3
Cetuximab
3
vandetanib
2
ulixertinib
2
omipalisib
2
larotrectinib
2
defactinib
2
copanlisib
2
cemiplimab
2
anlotinib
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Sodium Iodide
×
1 year
×
Clear all
NCT01398085
2026-05-07
IoN
University College, London
Phase 2/3
Active not recruiting
504 enrolled